• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Live Link
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • News
    • Careers

Get started
Sign in
Close
Crohn’s disease and the power of complete, timely, and clean EHR data

Crohn’s disease and the power of complete, timely, and clean EHR data

by Truveta staff | Jan 18, 2024 | Research

Crohn’s disease, a complex chronic inflammatory disorder of the GI tract, affects approximately 780,000 Americans with an estimated 33,000 new cases diagnosed each year. Crohn’s, along with ulcerative colitis, are the two major forms of inflammatory bowel disease...
Understanding the potential relationship between mental health and cannabis use

Understanding the potential relationship between mental health and cannabis use

by Truveta Research | Jan 11, 2024 | Research, Research Insights

There is a complex relationship between cannabis use and mental health. We studied recent time trends of the rate of cannabis-induced disorder emergency department visits and cannabis-involved emergency department visits (both defined below). Between 2019 and 2020, we...
First real-world comparative effectiveness study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

First real-world comparative effectiveness study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

by Truveta Research | Nov 27, 2023 | Research, Research Insights

In the first comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data, Truveta Research found that patients with overweight or obesity taking tirzepatide were three times more likely to achieve 15%...
Top reasons Truveta Data is the best real world data for studying diabetes

Top reasons Truveta Data is the best real world data for studying diabetes

by Truveta staff | Nov 16, 2023 | Research

In the world of healthcare, few conditions have seen as much transformation over the past decade as diabetes. With 37.3 million Americans living with diabetes, and a further 96 million in the prediabetes stage, it’s a life-altering health concern for nearly 40% of the...
Real-world prescribing of long-acting injectable cabotegravir for treatment of HIV in the United States

Real-world prescribing of long-acting injectable cabotegravir for treatment of HIV in the United States

by Truveta Research | Nov 10, 2023 | Research, Research Insights

Adequate treatments are a crucial piece in the fight against the spread of HIV, because they can make HIV viral load undetectable in the blood and thus untransmittable. Approved by the US Food and Drug Administration (FDA) in January 2021, one of the newest treatments...
Real-world trends in APOE genetic testing associated with lecanemab

Real-world trends in APOE genetic testing associated with lecanemab

by Truveta Research | Nov 10, 2023 | Research, Research Insights

Lecanemab received accelerated FDA approval in January 2023 and full FDA approval in July 2023. A potential side effect of the drug is brain swelling and/or small hemorrhages and is most common for people with the APOE ε4 genetic variant, therefore rates of APOE e4...
« Older Entries
Next Entries »

Share this


Recent posts

  • Real-world evidence on heart failure from GLP-1 and advanced CKD populations
  • Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval
  • Use of GLP-1 RAs following label expansion for patients with CVD and overweight or obesity

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Research

Resources

Blog

News

Careers

Privacy notice

Contact us

© Truveta 2026

Our website uses cookies to ensure you have the best experience.